After listeners asked for more following the earlier peptides show, the podcast now looks at what the science says about collagen supplements.
Recap by typeshit. Post by @science_vs on Instagram.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
Adding an experimental hormone mimic to tirzepatide pushed body mass reduction as high as 23.3% in a Lilly clinical trial, per NewsBytes.
Novo also presented liver fat data from STEP-UP and an Ozempic vs Mounjaro heart risk analysis, and paid $300 million upfront for Hengrui's HRS-1596.
Loading…